Search PubMed⌕ Search

Biomedical subjects

G Velluti

Publications and source records attributed to G Velluti.

At least 37 records · Page 2Linked to original sources
PubMed1975

[Recent studies on the in vivo and in vitro activity of gentamicin].

The effect of gentamycin was investigated at the University of Modena Phthisiology and Respiratory Diseases Department. In vitro activity against most pathological Gram-positive and Gram-negative bacteria was observed. A dose of 4-5 mg/kg proved very effective in cases of bacteria-induced bronchopneumopathy. The drug was also active against penicillin-resistant staphylococci and Gram-negative bacteria with a known resistance to ordinary antibiotics.

Acinetobacter↗
PubMedDate not supplied

[Mycobacterial infections in man: bacteriological, clinical and epidemiological evaluation (author's transl)].

At present time the direct microscopy of acid-alcohol fast bacteria includes Mycobacteria, Nocardia, "rhodochrous complex". Direct microscopy is suitable to identify visible and not viable bacteria, the debacillization curve and the fall and rise phenomenon. Strains of M. tuberculosis complex are frequently with partial virulence low infectivity, and are modified by drugs. Little or no reaction to PPD is present.

Anti-Bacterial Agents↗
PubMedDate not supplied

[Treatment of tuberculosis].

Tuberculosis appears to be a diagnostic challenge and an important therapeutical problem in industrialized and in developing countries, where most infections occur. Besides several rifamycin derivatives, new molecules (fluorinated quinolones, macrolides, beta-lactam antibiotics) are being explored in the face of increasing bacterial-resistance with the aim of improving the efficacy and safety of anti-tuberculous drugs, shortening the period of treatment or allowing intermittent regimens. At present, in severe forms of the disease three or more of the available anti-tuberculous agents must be administered simultaneously for at least 3-4 months and two for the following 6-7 months. Nevertheless, a variety of highly effective 6 months regimens are currently used for the treatment of less severe tuberculosis.

Antitubercular Agents↗
PubMedDate not supplied

[Treatment of mycobacteriosis].

At present the increased incidence of infections with mycobacteria other than tuberculosis and leprae bacilli seems to be correlated with several causes: improved diagnostic techniques, prolonged life expectancy, immunodepression. Rational chemotherapy depends upon the identification of the etiologic mycobacterium and the determination of its drug susceptibility. Besides the "classic" treatment with 3 or 4 antituberculous and, sometimes, nonantituberculous chemotherapics, clinical trials are in progress to assess the effectiveness of new molecules: rifamycin derivatives, fluorinated quinolones, anti-lepromatous drugs, and the latest macrolides. Yet at present, national and international data do not permit to define a standard treatment for every mycobacteriosis; in fact, the drug resistance is high and varies not only between different strains but also within the same strain; moreover, there are discrepancies between in vitro and in vivo results. When possible, appropriated surgery for circumscribed disease is recommended.

Acquired Immunodeficiency Syndrome↗